Pfizer Inc. (PFE) EV/Assets Ratio: 1.01x
Is Pfizer Inc.’s EV/Assets ratio high or low?
Pfizer Inc.'s EV/Assets ratio of 1.01x is 21% below its 5-year average of 1.28x, near the low end of its 5-year range (0.88x–2.16x).
The EV/Assets ratio for Pfizer Inc. (PFE) is 1.01x as of Wednesday, June 10, 2026. It is above its 12-month average by 1.02% (1.00x).
PFE EV/Assets Ratio Chart
PFE Average EV/Assets Ratio Chart
PFE Current vs Average EV/Assets Ratio Chart
PFE EV/Assets Ratio Metrics
EV/ASSETS RATIO
1.01x
EV/ASSETS RATIO AVG TTM
1.00x
EV/ASSETS RATIO AVG 3Y
1.03x
EV/ASSETS RATIO AVG 5Y
1.28x
EV/ASSETS RATIO AVG 10Y
1.39x
EV/ASSETS RATIO AVG 15Y
1.34x
EV/ASSETS RATIO AVG 20Y
1.31x
CURRENT VS TTM AVG
+1.02%
CURRENT VS 3Y AVG
-1.93%
CURRENT VS 5Y AVG
-21.23%
CURRENT VS 10Y AVG
-27.50%
CURRENT VS 15Y AVG
-24.62%
CURRENT VS 20Y AVG
-22.85%
PFE Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $146.36B | 1.01x | 1.00x | 1.03x | 1.28x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 7.30x | 8.88x | 9.09x | 8.50x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 2.97x | 3.05x | 2.44x | 2.15x |
| Abbott Laboratories (ABT) | $154.66B | 1.65x | 2.50x | 2.67x | 2.75x |
| Danaher Corporation (DHR) | $130.25B | 1.72x | 1.98x | 2.16x | 2.26x |
| CVS Health Corporation (CVS) | $125.16B | 0.77x | 0.67x | 0.63x | 0.70x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.72x | 1.55x | 1.56x | 1.64x |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 1.94x | 2.16x | 2.33x | 2.57x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 4.10x | 4.45x | 4.69x | 4.46x |
| Amgen Inc. (AMGN) | $183.75B | 2.49x | 2.46x | 2.27x | 2.38x |
Pfizer Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Pfizer Inc. (PFE)?
- The EV/Assets ratio for PFE stock is 1.01x.
- Is Pfizer Inc.'s EV/Assets ratio high or low?
- Pfizer Inc.'s EV/Assets ratio of 1.01x is 21% below its 5-year average of 1.28x, near the low end of its 5-year range (0.88x–2.16x).
- What is the TTM average EV/Assets ratio for Pfizer Inc. (PFE)?
- The TTM average EV/Assets ratio for PFE stock is 1.00x.
- What is the 3Y average EV/Assets ratio for Pfizer Inc. (PFE)?
- The 3Y average EV/Assets ratio for PFE stock is 1.03x.
- What is the 5Y average EV/Assets ratio for Pfizer Inc. (PFE)?
- The 5Y average EV/Assets ratio for PFE stock is 1.28x.
- What is the 10Y average EV/Assets ratio for Pfizer Inc. (PFE)?
- The 10Y average EV/Assets ratio for PFE stock is 1.39x.
- What is the 15Y average EV/Assets ratio for Pfizer Inc. (PFE)?
- The 15Y average EV/Assets ratio for PFE stock is 1.34x.
- What is the 20Y average EV/Assets ratio for Pfizer Inc. (PFE)?
- The 20Y average EV/Assets ratio for PFE stock is 1.31x.
Pfizer Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 1.01x |
| 2026-06-09 | 1.01x |
| 2026-06-08 | 1.01x |
| 2026-06-05 | 1.02x |
| 2026-06-04 | 1.01x |
| 2026-06-03 | 1.00x |
| 2026-06-02 | 1.01x |
| 2026-06-01 | 1.01x |
| 2026-05-29 | 1.02x |
| 2026-05-28 | 1.02x |
| 2026-05-27 | 1.03x |
| 2026-05-26 | 1.02x |
| 2026-05-22 | 1.02x |
| 2026-05-21 | 1.02x |
| 2026-05-20 | 1.01x |
| 2026-05-19 | 1.01x |
| 2026-05-18 | 1.00x |
| 2026-05-15 | 1.00x |
| 2026-05-14 | 1.01x |
| 2026-05-13 | 1.02x |
| 2026-05-12 | 1.02x |
| 2026-05-11 | 1.01x |
| 2026-05-08 | 1.01x |
| 2026-05-07 | 1.03x |
| 2026-05-06 | 1.03x |
| 2026-05-05 | 1.03x |
| 2026-05-04 | 1.04x |
| 2026-05-01 | 1.04x |
| 2026-04-30 | 1.05x |
| 2026-04-29 | 1.04x |
| 2026-04-28 | 1.04x |
| 2026-04-27 | 1.05x |
| 2026-04-24 | 1.06x |
| 2026-04-23 | 1.05x |
| 2026-04-22 | 1.05x |
| 2026-04-21 | 1.06x |
| 2026-04-20 | 1.07x |
| 2026-04-17 | 1.07x |
| 2026-04-16 | 1.06x |
| 2026-04-15 | 1.06x |
| 2026-04-14 | 1.06x |
| 2026-04-13 | 1.07x |
| 2026-04-10 | 1.05x |
| 2026-04-09 | 1.06x |
| 2026-04-08 | 1.07x |
| 2026-04-07 | 1.06x |
| 2026-04-06 | 1.08x |
| 2026-04-02 | 1.09x |
| 2026-04-01 | 1.10x |
| 2026-03-31 | 1.09x |
| 2026-03-30 | 1.08x |
| 2026-03-27 | 1.06x |
| 2026-03-26 | 1.07x |
| 2026-03-25 | 1.06x |
| 2026-03-24 | 1.05x |
| 2026-03-23 | 1.05x |
| 2026-03-20 | 1.06x |
| 2026-03-19 | 1.07x |
| 2026-03-18 | 1.06x |
| 2026-03-17 | 1.07x |
| 2026-03-16 | 1.05x |
| 2026-03-13 | 1.04x |
| 2026-03-12 | 1.05x |
| 2026-03-11 | 1.06x |
| 2026-03-10 | 1.06x |
| 2026-03-09 | 1.05x |
| 2026-03-06 | 1.06x |
| 2026-03-05 | 1.05x |
| 2026-03-04 | 1.05x |
| 2026-03-03 | 1.04x |
| 2026-03-02 | 1.06x |
| 2026-02-27 | 1.07x |
| 2026-02-26 | 1.06x |
| 2026-02-25 | 1.03x |
| 2026-02-24 | 1.03x |
| 2026-02-23 | 1.03x |
| 2026-02-20 | 1.02x |
| 2026-02-19 | 1.02x |
| 2026-02-18 | 1.04x |
| 2026-02-17 | 1.04x |
| 2026-02-13 | 1.04x |
| 2026-02-12 | 1.04x |
| 2026-02-11 | 1.05x |
| 2026-02-10 | 1.05x |
| 2026-02-09 | 1.03x |
| 2026-02-06 | 1.03x |
| 2026-02-05 | 1.01x |
| 2026-02-04 | 1.02x |
| 2026-02-03 | 0.99x |
| 2026-02-02 | 1.02x |
| 2026-01-30 | 1.01x |
| 2026-01-29 | 1.00x |
| 2026-01-28 | 1.00x |
| 2026-01-27 | 1.01x |
| 2026-01-26 | 1.00x |
| 2026-01-23 | 0.99x |
| 2026-01-22 | 1.00x |
| 2026-01-21 | 1.00x |
| 2026-01-20 | 0.99x |
| 2026-01-16 | 0.99x |
| 2026-01-15 | 1.00x |
| 2026-01-14 | 0.99x |
| 2026-01-13 | 0.98x |
| 2026-01-12 | 0.98x |
| 2026-01-09 | 0.99x |
| 2026-01-08 | 0.98x |
| 2026-01-07 | 0.98x |
| 2026-01-06 | 0.99x |
| 2026-01-05 | 0.98x |
| 2026-01-02 | 0.98x |
| 2025-12-31 | 0.97x |
| 2025-12-30 | 0.97x |
| 2025-12-29 | 0.97x |
| 2025-12-26 | 0.98x |
| 2025-12-24 | 0.97x |
| 2025-12-23 | 0.97x |
| 2025-12-22 | 0.98x |
| 2025-12-19 | 0.98x |
| 2025-12-18 | 0.97x |
| 2025-12-17 | 0.97x |
| 2025-12-16 | 0.99x |
| 2025-12-15 | 1.01x |
| 2025-12-12 | 1.00x |
| 2025-12-11 | 1.00x |
| 2025-12-10 | 0.99x |
| 2025-12-09 | 0.98x |
| 2025-12-08 | 0.99x |
| 2025-12-05 | 1.00x |
| 2025-12-04 | 0.99x |
| 2025-12-03 | 0.99x |
| 2025-12-02 | 0.98x |
| 2025-12-01 | 0.98x |
| 2025-11-28 | 0.99x |
| 2025-11-26 | 0.99x |
| 2025-11-25 | 0.99x |
| 2025-11-24 | 0.98x |
| 2025-11-21 | 0.97x |
| 2025-11-20 | 0.96x |
| 2025-11-19 | 0.97x |
| 2025-11-18 | 0.99x |
| 2025-11-17 | 0.98x |
| 2025-11-14 | 0.98x |
| 2025-11-13 | 1.00x |
| 2025-11-12 | 1.00x |
| 2025-11-11 | 0.99x |
| 2025-11-10 | 0.96x |
| 2025-11-07 | 0.96x |
| 2025-11-06 | 0.97x |
| 2025-11-05 | 0.96x |
| 2025-11-04 | 0.95x |
| 2025-11-03 | 0.97x |
| 2025-10-31 | 0.97x |
| 2025-10-30 | 0.96x |
| 2025-10-29 | 0.96x |
| 2025-10-28 | 0.97x |
| 2025-10-27 | 0.98x |
| 2025-10-24 | 0.98x |
| 2025-10-23 | 0.97x |
| 2025-10-22 | 0.98x |
| 2025-10-21 | 0.98x |
| 2025-10-20 | 0.98x |
| 2025-10-17 | 0.97x |
| 2025-10-16 | 0.96x |
| 2025-10-15 | 0.97x |
| 2025-10-14 | 0.97x |
| 2025-10-13 | 0.98x |
| 2025-10-10 | 0.98x |
| 2025-10-09 | 0.99x |
| 2025-10-08 | 1.00x |
| 2025-10-07 | 1.02x |
| 2025-10-06 | 1.02x |
| 2025-10-03 | 1.05x |
| 2025-10-02 | 1.04x |
| 2025-10-01 | 1.05x |
| 2025-09-30 | 1.00x |
| 2025-09-29 | 0.95x |
| 2025-09-26 | 0.95x |
| 2025-09-25 | 0.95x |
| 2025-09-24 | 0.96x |
| 2025-09-23 | 0.96x |
| 2025-09-22 | 0.96x |
| 2025-09-19 | 0.96x |
| 2025-09-18 | 0.96x |
| 2025-09-17 | 0.96x |
| 2025-09-16 | 0.95x |
| 2025-09-15 | 0.96x |
| 2025-09-12 | 0.95x |
| 2025-09-11 | 0.98x |
| 2025-09-10 | 0.97x |
| 2025-09-09 | 0.98x |
| 2025-09-08 | 0.97x |
| 2025-09-05 | 0.98x |
| 2025-09-04 | 0.97x |
| 2025-09-03 | 0.98x |
| 2025-09-02 | 0.98x |
| 2025-08-29 | 0.98x |
| 2025-08-28 | 0.97x |
| 2025-08-27 | 0.99x |
| 2025-08-26 | 0.98x |
| 2025-08-25 | 0.99x |
| 2025-08-22 | 1.01x |
| 2025-08-21 | 1.00x |
| 2025-08-20 | 0.99x |
| 2025-08-19 | 0.99x |
| 2025-08-18 | 0.99x |
| 2025-08-15 | 0.99x |
| 2025-08-14 | 0.99x |
| 2025-08-13 | 0.99x |
| 2025-08-12 | 0.97x |
| 2025-08-11 | 0.97x |
| 2025-08-08 | 0.97x |
| 2025-08-07 | 0.96x |
| 2025-08-06 | 0.95x |
| 2025-08-05 | 0.98x |
| 2025-08-04 | 0.93x |
| 2025-08-01 | 0.93x |
| 2025-07-31 | 0.93x |
| 2025-07-30 | 0.94x |
| 2025-07-29 | 0.95x |
| 2025-07-28 | 0.96x |
| 2025-07-25 | 0.97x |
| 2025-07-24 | 0.98x |
| 2025-07-23 | 0.98x |
| 2025-07-22 | 0.98x |
| 2025-07-21 | 0.95x |
| 2025-07-18 | 0.96x |
| 2025-07-17 | 0.96x |
| 2025-07-16 | 0.96x |
| 2025-07-15 | 0.96x |
| 2025-07-14 | 0.98x |
| 2025-07-11 | 0.99x |
| 2025-07-10 | 1.00x |
| 2025-07-09 | 0.99x |
| 2025-07-08 | 0.99x |
| 2025-07-07 | 0.98x |
| 2025-07-03 | 0.98x |
| 2025-07-02 | 0.98x |
| 2025-07-01 | 0.98x |
| 2025-06-30 | 0.95x |
| 2025-06-27 | 0.95x |
| 2025-06-26 | 0.95x |
| 2025-06-25 | 0.95x |
| 2025-06-24 | 0.96x |
| 2025-06-23 | 0.95x |
| 2025-06-20 | 0.95x |
| 2025-06-18 | 0.94x |
| 2025-06-17 | 0.95x |
| 2025-06-16 | 0.96x |
| 2025-06-13 | 0.96x |
| 2025-06-12 | 0.97x |
| 2025-06-11 | 0.96x |
| 2025-06-10 | 0.95x |
| 2025-06-09 | 0.95x |
| 2025-06-06 | 0.93x |
| 2025-06-05 | 0.92x |
| 2025-06-04 | 0.93x |
| 2025-06-03 | 0.93x |
| 2025-06-02 | 0.93x |
| 2025-05-30 | 0.93x |
| 2025-05-29 | 0.93x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla